Slingshot members are tracking this event:

FDA Accepts and Grants Priority Review for AVYCAZ (ceftazidime and avibactam) Supplemental New Drug Application (sNDA)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
AGN Community voting in process

Additional Information

Additional Relevant Details Application Seeks to Expand AVYCAZ Label to Include Phase 3 Clinical Data for the Treatment of Complicated Intra-Abdominal Infections (cIAI), in Combination with Metronidazole
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 24, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Avycaz, Ceftazidime, Avibactam, Snda, Caz-ns, Metronidazole, Complicated Intra-abdominal Infections, Ciai, Ceftazidime-nonsusceptible Pathogens